Godavari Drugs Share Price

120.50-3.10 (-2.50%)

BSE

Closed
As On:
As On: 25 Jun, 2026, 03:31 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

STOCK SCORE

Unlock Scores

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	-
High	-
Low	-
Prev Close	-
Volume	-
VWAP(₹)	-

Share Price	Value
Today/Current/Last	-120.50
Previous Day	-123.60

Godavari Drugs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Godavari Drugs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	33.30	22.20	27.28	23.82	25.61
Total Income Growth (%)	50.02	-18.63	14.53	-6.97	-13.63
Total Expenses	30.73	20.07	25.26	21.52	23.06
Total Expenses Growth (%)	53.14	-20.54	17.37	-6.70	-16.50
EBIT	2.57	2.13	2.03	2.31	2.55
EBIT Growth (%)	20.63	5.09	-12.02	-9.43	25.40
Profit after Tax (PAT)	1.29	0.76	1.00	1.04	0.89
PAT Growth (%)	70.38	-24.29	-3.83	16.52	16.38
EBIT Margin (%)	7.73	9.61	7.44	9.68	9.95
Net Profit Margin (%)	3.88	3.41	3.67	4.37	3.49
Basic EPS (₹)	1.71	1.01	1.33	1.38	1.19

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	106.61	114.33	157.33	160.28	161.38
Total Revenue Growth (%)	-6.75	-27.33	-1.84	-0.68	31.12
Total Expenses	101.91	108.70	150.32	155.57	154.36
Total Expenses Growth (%)	-6.25	-27.68	-3.38	0.79	31.51
Profit after Tax (PAT)	4.09	4.38	5.55	3.79	5.25
PAT Growth (%)	-6.64	-21.07	46.57	-27.82	27.06
Operating Profit Margin (%)	8.21	9.13	7.61	5.40	6.12
Net Profit Margin (%)	3.86	3.86	3.54	2.37	3.25
Basic EPS (₹)	5.43	5.82	7.37	5.03	6.97

All figures in Rs Cr, unless mentioned otherwise

Insights

Quarterly Topline Performance
Company witnessed QoQ revenue growth of 50.02%, which is highest in the last 3 years. (Source: Standalone Financials)
Employee & Interest Expense
Company has spent 3.76% of its operating revenues towards interest expenses and 5.38% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	200.43	143.08	134.75	121.43	101.41
Total Assets Growth (%)	40.08	6.18	10.97	19.74	11.27
Total Liabilities	124.63	99.73	95.79	88.02	71.78
Total Liabilities Growth (%)	24.97	4.11	8.83	22.62	7.54
Total Equity	75.80	43.35	38.97	33.42	29.63
Total Equity Growth (%)	74.86	11.24	16.61	12.79	21.48
Current Ratio (x)	1.31	1.08	1.08	1.18	1.29
Total Debt to Equity (x)	1.01	1.42	1.43	1.00	0.69
Contingent Liabilities	0.00	0.50	0.50	0.50	0.39

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	0.73	11.20	18.41	13.22	11.23
Net Cash used in Investing Activities	-25.95	-19.51	-13.22	-8.64	-4.97
Net Cash flow from Financing Activities	37.35	8.07	-5.65	-3.77	-5.62
Net Cash Flow	12.14	-0.25	-0.46	0.81	0.64
Closing Cash & Cash Equivalent	14.51	2.37	2.62	3.08	2.28
Closing Cash & Cash Equivalent Growth (%)	511.36	-9.52	-14.97	35.51	38.95
Total Debt/ CFO (x)	104.10	5.50	3.02	2.53	1.81

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 0.73 cr is 0.18 times compared to the reported net profit of Rs 4.09 cr. (Source: Standalone Financials)
Increase in Cash from Investing
Company has used Rs 25.95 cr for investing activities which is an YoY increase of 32.98%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	5.39	10.10	14.24	11.32	17.70
Return on Capital Employed (%)	7.53	14.79	22.60	18.08	22.61
Return on Assets (%)	2.04	3.06	4.11	3.11	5.17
Interest Coverage Ratio (x)	2.79	2.71	2.83	2.69	4.06
Asset Turnover Ratio (x)	0.62	0.82	1.22	1.43	1.67
Price to Earnings (x)	21.32	15.06	12.63	15.08	9.40
Price to Book (x)	1.15	1.52	1.80	1.71	1.66
EV/EBITDA (x)	13.40	9.77	8.83	8.27	5.82
EBITDA Margin (%)	10.50	11.29	8.88	6.62	7.17

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Godavari Drugs	29.84	1.61	5.39	7.53	2.04	-12.59	8.21	3.86	5.43	1.31	1.01	104.10
Alpa Labs	10.17	0.78	7.58	8.94	5.83	5.85	16.02	13.35	6.71	4.01	0.01	0.24
Krebs Biochem	-8.38	-0.87	0.00	-19.62	-10.37	-21.07	-41.49	-71.35	-7.85	0.09	-1.38	-117.07
Smruthi Org	38.98	1.82	4.66	8.84	3.30	-10.14	6.67	3.35	2.99	1.98	0.11	0.38
Bal Pharma	21.18	1.62	7.68	18.01	1.68	0.90	7.30	2.02	3.95	1.05	1.94	20.28
Add More

Annual Ratios (%)

Choose from Peers

Aayush Food & Herbs
Lactose (India)
Tyche Inds
Pharmaids Pharm
Mercury Laboratories

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Godavari Drugs Stock Performance	-2.50	-5.12	3.01	43.83	25.26	49.56	98.19
Alpa Labs Stock Performance	-0.49	2.22	0.04	2.92	-35.54	17.65	21.59
Krebs Biochem Stock Performance	0.00	0.00	10.67	9.77	-11.84	0.35	-48.85
Smruthi Org Stock Performance	0.82	0.47	3.28	4.90	-15.38	-25.01	-57.11
Bal Pharma Stock Performance	-0.72	5.84	8.30	6.54	-16.57	-2.44	-13.46
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	40,74,091	40.23 %	-12.38
Pledge	8,531	0.21 %	-0.01
DII	2,12,360	2.10 %	-
MF	1,00,000	0.99 %	-
Others	58,40,984	57.67 %	10.28

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	40.23	52.61	52.61	52.63
Pledge	0.21	0.22	0.22	0.25
FII	0.00	0.00	0.00	0.00
DII	2.10	0.00	0.00	0.00
Mutual Funds	0.99	0.00	0.00	0.00
Others	57.67	47.39	47.39	47.37

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Quarterly Results
Feb 09, 2026
General Meeting
-
Jan 21, 2026
Board Meeting
Preferential issue of shares
Jan 12, 2026

Board Meetings

Announced on	Meeting on
Feb 09, 2026	Feb 11, 2026
Quarterly Results
Jan 12, 2026	Jan 15, 2026
Preferential issue of shares
Nov 07, 2025	Nov 14, 2025
Quarterly Results
Aug 01, 2025	Aug 13, 2025
Quarterly Results & A.G.M.
May 26, 2025	May 29, 2025
Audited Results

Dividends
Announced on Ex-Date Dividend%
Aug 17, 1998 - 22%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available

Announced on	Ex-Date	Dividend%
Aug 17, 1998	-	22%

AGM/EGM Meetings

Announced on	Meeting on
Jan 21, 2026	Feb 12, 2026
-
Aug 04, 2025	Sep 27, 2025
(Revised)
Aug 04, 2025	Aug 13, 2025
-
Aug 05, 2024	Aug 29, 2024
Book closure from Aug 24, 2024 to Aug 29, 2024
Jul 21, 2023	Aug 12, 2023
A.G.M.

About Godavari Drugs

Godavari Drugs Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 122.04 Crore) operating in Pharmaceuticals sector.

Godavari Drugs Ltd. key Products/Revenue Segments include Bulk Drugs, Income From Construction Work and Raw Materials for the year ending 31-Mar-2017.

For the quarter ended 31-03-2026, the company has reported a Standalone Total Income of Rs 33.30 Crore, up 50.02 % from last quarter Total Income of Rs 22.20 Crore and up 30.06 % from last year same quarter Total Income of Rs 25.61 Crore. Company has reported net profit after tax of Rs 1.29 Crore in latest quarter.

The company’s top management includes Mr.Ghanshyam Jaju, Mr.Mukund Kakani, Mr.Mohit Jaju, Mr.Dinesh Udpa, Mr.Mahendra Bhalerao, Mrs.Shilpa Bung, Mrs.Venkatesh Achanta. Company has V Sridhar & Co. as its auditors. As on 31-03-2026, the company has a total of 1.01 Crore shares outstanding.

Godavari Drugs Share Price Today is Rs. 120.50. On previous day, the Godavari Drugs Share Price (NSE) closed at Rs. 123.6, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 40.23% of the stake in Godavari Drugs shares, out of which 0.21% was pledged. On the same date, foreign institutional investors' (FII) holdings of Godavari Drugs stocks was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 2.1% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Godavari Drugs shares 0.99% was held by mutual funds. The rest including public held is 0.0%. Godavari Drugs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Godavari Drugs Dividend: Ever since 1987, Godavari Drugs dividends has been paid out around 1 times. As on 25 Jun, 2026, 03:31 PM IST, The overall dividend yield for Godavari Drugs stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 4.04.

Godavari Drugs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 33.3 Cr. of sales and 50.02% of quarterly net profit, there have been multiple ups and downs in the Godavari Drugs stock prices in the past few weeks. For example, Godavari Drugs stock price on 18th of June 2026 was around Rs. 125.0. Godavari Drugs share price now stands at an average of Rs. 120.50. Judging by last week's performance, stock is in down trend.

Godavari Drugs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Godavari Drugs share.

Historical Prices and Performance:
Godavari Drugs, incorporated in 1987 is a Small Cap company (with a market cap of Rs. 122.04) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Godavari Drugs stock was 5.39%, 10.1%, 14.24%, 11.32% and 17.7% respectively.
The Godavari Drugs share gave a 3 year return of 25.7% as compared to Nifty 50 which gave a return of 28.88%.
Godavari Drugs announced 22.0% final dividend on null.

Key Metrics:
PE Ratio of Godavari Drugs is 30.87
Prices/Sales Ratio of Godavari Drugs is 0.82
Price/Book Ratio of Godavari Drugs is 1.67

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at 30.87 and 1.67 respectively.

Leadership of Godavari Drugs :
Venkatesh Achanta is Co. Secretary & Compl. Officer
Ghanshyam Jaju is Chairman
Mukund Kakani is Managing Director
Mohit Jaju is WholeTime Director & CFO
Mahendra Bhalerao is Ind. Non-Executive Director
Dinesh Udpa is Ind. Non-Executive Director
Shilpa Bung is Ind. Non-Executive Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

1-8-303/34,Mayfair,Secunderabad, Telangana - 500003

Contact

info@godavaridrugs.com

http://www.godavaridrugs.com

PE Ratio(x)	29.84
EPS - TTM(₹)	4.04
MCap(₹ Cr.)	122.04
MCap Rank	137
PB Ratio(x)	1.67
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	135.25
52W Low(₹)	69.70
MCap/Sales	0.82
Beta(1 Month)	-0.47
BV/Share(₹)	74.85

1 Day	-2.5%
1 Month	-6.52%
3 Months	33.84%
1 Year	29.06%
3 Years	26.68%
5 Years	94.67%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Godavari Drugs Share Price

Key Metrics